Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Marianna VeraldiRossella Di Bidino

Abstract

Non-small-cell lung carcinoma (NSCLC) accounts for 85-90% of all forms of lung cancer. Immuno-oncology represents a valid new approach but the high cost requires a specific evaluation of the health outcomes. This study describes the real-world efficacy, safety and cost profiles of the new anti-PD-1 immune-checkpoint inhibitors nivolumab and pembrolizumab on a cohort of 56 selected patients with advanced NSCLC. A retrospective, observational analysis was conducted on patients treated with immune checkpoint inhibitors from September 2015 to September 2018 at Azienda Ospedaliera Universitaria "Mater Domini" in Catanzaro, Italy. Data sources were medical records, internal prescription cards and reports of adverse reactions. Fifty-six patients were diagnosed with advanced NSCLC, 64.3% characterized by a non-squamous histology, 30.3% squamous and 5.4% not specified. First-line treatment with pembrolizumab was administered to 11 patients for an average of 4.4 months, while 45 patients were treated with nivolumab for an average of 8.6 months. Data showed a survival rate of 95% after 6 months and 88% after 12 months. Most patients received immunotherapy as a second-line or subsequent treatment. In terms of prior therapy among all the pa...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Jun 10, 2004·JAMA : the Journal of the American Medical Association·Vivek H MurthyCary P Gross
Sep 23, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Marjolein PompenPieter Postmus
Dec 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio ScagliottiChandra P Belani
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Apr 21, 2016·Future Oncology·Marc L BergerAmy P Abernethy
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Apr 14, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Etienne Giroux LeprieurThierry Chinet
Aug 15, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sandra GarciaDavid E Gerber
Nov 28, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·W R KeustersG W J Frederix
Jul 15, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerMiranda Hughes
Jul 28, 2018·Translational Lung Cancer Research·Mª Carmen Areses ManriqueJosé Luis Fírvida Pérez
Feb 1, 2019·Nature Reviews. Clinical Oncology·Christopher M BoothWilliam J Mackillop
Feb 5, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardS Peters
Aug 2, 2019·Translational Lung Cancer Research·Sawsan Rashdan, David E Gerber
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardS Peters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.